HR 4472

BENEFIT Act of 2021

Congress: 117 (2021–2023, Ended)
Chamber: House
Policy Area: Health
Introduced: Jul 16, 2021
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Jul 19, 2021)
Official Text: https://www.congress.gov/bill/117th-congress/house-bill/4472

Sponsor

Name: Rep. Matsui, Doris O. [D-CA-6]
Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (17 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Wenstrup, Brad R. [R-OH-2]	R · OH		Jul 16, 2021
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Jul 21, 2021
Rep. LaMalfa, Doug [R-CA-1]	R · CA		Aug 13, 2021
Rep. Cárdenas, Tony [D-CA-29]	D · CA		Nov 4, 2021
Rep. Bacon, Don [R-NE-2]	R · NE		Jan 20, 2022
Rep. Bishop, Sanford D., Jr. [D-GA-2]	D · GA		Mar 2, 2022
Rep. Wild, Susan [D-PA-7]	D · PA		Mar 8, 2022
Rep. Soto, Darren [D-FL-9]	D · FL		Mar 9, 2022
Rep. Fortenberry, Jeff [R-NE-1]	R · NE		Mar 11, 2022
Rep. Higgins, Brian [D-NY-26]	D · NY		Mar 11, 2022
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Mar 15, 2022
Rep. Cleaver, Emanuel [D-MO-5]	D · MO		Mar 15, 2022
Rep. Cole, Tom [R-OK-4]	R · OK		Mar 16, 2022
Rep. Norman, Ralph [R-SC-5]	R · SC		Mar 17, 2022
Resident Commissioner González-Colón, Jenniffer [R-PR-At Large]	R · PR		Apr 18, 2022
Rep. Kim, Young [R-CA-39]	R · CA		Apr 27, 2022
Rep. DeSaulnier, Mark [D-CA-11]	D · CA		May 27, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jul 19, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 373	Identical bill	**Feb 23, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jul 16, 2021)

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021 or the BENEFIT Act of 2021

This bill requires the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs.

After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.

Actions Timeline

- **Jul 19, 2021:** Referred to the Subcommittee on Health.
- **Jul 16, 2021:** Introduced in House
- **Jul 16, 2021:** Referred to the House Committee on Energy and Commerce.